These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Murmurs from the heart (or why the stethoscope is not an economic tool). Aristides M; Gliksman M Heart; 1998 Jan; 79(1):10-1. PubMed ID: 9518073 [No Abstract] [Full Text] [Related]
10. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L; N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425 [TBL] [Abstract][Full Text] [Related]
11. On the use of abciximab in percutaneous coronary intervention. Iversen AZ Dan Med Bull; 2011 Aug; 58(8):B4312. PubMed ID: 21827726 [No Abstract] [Full Text] [Related]
12. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. Stone GW; Grines CL; Cox DA; Garcia E; Tcheng JE; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Carroll JD; Rutherford BD; Lansky AJ; N Engl J Med; 2002 Mar; 346(13):957-66. PubMed ID: 11919304 [TBL] [Abstract][Full Text] [Related]
13. Interventional therapy for coronary artery disease. Shah PB; Lilly CM Am J Respir Crit Care Med; 2002 Sep; 166(6):791-6. PubMed ID: 12231486 [No Abstract] [Full Text] [Related]
14. Introduction: glycoprotein IIb/IIIa blockers in the era of metallic coronaries. Goldschmidt-Clermont PJ J Invasive Cardiol; 2002 Dec; 14 Suppl E():1E. PubMed ID: 12668856 [No Abstract] [Full Text] [Related]
15. Platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary revascularization: what more needs to be proven? Lincoff AM; Topol EJ Eur Heart J; 2000 Jun; 21(11):863-7. PubMed ID: 10806004 [No Abstract] [Full Text] [Related]
16. Preventing coronary restenosis and complications. Holmes DR N Engl J Med; 1997 Jun; 336(24):1748-9. PubMed ID: 9180094 [No Abstract] [Full Text] [Related]
17. Safety and efficacy of the platelet glycoprotein IIb/IIIa inhibitor abciximab in Chinese patients undergoing high-risk angioplasty. Chen YH; Chen JW; Wu TC; Ding PY; Wang SP; Chang MS Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jan; 63(1):8-15. PubMed ID: 10645045 [TBL] [Abstract][Full Text] [Related]
18. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Greenbaum AB; Grines CL; Bittl JA; Becker RC; Kereiakes DJ; Gilchrist IC; Clegg J; Stankowski JE; Grogan DR; Harrington RA; Emanuelsson H; Weaver WD Am Heart J; 2006 Mar; 151(3):689.e1-689.e10. PubMed ID: 16504633 [TBL] [Abstract][Full Text] [Related]
20. The use of abciximab during percutaneous coronary angioplasty reduces ischaemic events, but the cost is prohibitive. Mayosi BM; Latouf SE; Commerford PJ S Afr Med J; 1998 Feb; 88(2):130-1. PubMed ID: 9717492 [No Abstract] [Full Text] [Related] [Next] [New Search]